Barclays
CRDL

Barclays’s Cardiol Therapeutics CRDL Stock Holding History

Barclays’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$270 Buy
+200
New +$205 ﹤0.01% 4943

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays's CRDL Position: Q1 2026 in Review

Barclays opened a new position in Cardiol Therapeutics (CRDL) in Q1 2026: 200 shares worth $270. The stake represents ﹤0.01% of the portfolio and ranks #4943 among its holdings.

47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Barclays held 200 shares of Cardiol Therapeutics worth $270 as of Q1 2026.
  • Cardiol Therapeutics was a new Barclays position in Q1 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4943 holding.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.